Esophageal Cancer

Latest News

Long-term survival benefit is seen in patients with treatment-naïve advanced esophageal squamous cell carcinoma who were treated with nivolumab plus chemotherapy or ipilimumab.
Nivolumab/Ipilimumab or Chemo Yields Long-Lasting Survival Benefit in Esophageal Cancer

January 20th 2023

Long-term survival benefit is seen in patients with treatment-naïve advanced esophageal squamous cell carcinoma who were treated with nivolumab plus chemotherapy or ipilimumab.

Results from a randomized controlled trial highlighted that the TissueCypher Barrett’s Esophagus Test heightened accuracy for assessing progression risk in high-grade dysplasia and esophageal adenocarcinoma among patients with Barrett’s esophagus.
TissueCypher Barrett’s Esophagus Test Increases Risk Assessment Accuracy in High-Grade Dysplasia/Esophageal Adenocarcinoma

October 18th 2022

Patients with ERBB2-positive esophagogastric adenocarcinoma appeared to experience improved efficacy following treatment with a combination of trastuzumab and nivolumab plus leucovorin, fluorouracil, and oxaliplatin vs historical data.
FOLFOX Plus Trastuzumab and Nivolumab Demonstrated Promising Efficacy in ERBB2+ Esophagogastric Adenocarcinoma

July 19th 2022

FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab for Unresectable Advanced ESCC
FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab for Unresectable Advanced ESCC

May 31st 2022

Although patients with stage I esophageal cancer who received early surgery had similar survival vs delayed surgery, those with stage II and III disease experienced improved outcomes.
Early Vs Delayed Surgery Associated With Improved Survival in Stage II/III Esophageal Cancer

May 13th 2022

Video Interviews
Podcasts

More News